Guided Therapeutics (GTHP) Common Equity (2010 - 2025)

Guided Therapeutics has disclosed Common Equity across 16 years of filings, most recently posting -$6.0 million for Q4 2025.

• Common Equity for Q4 2025 came in at -$6.0 million, down 22.72% year-over-year; the trailing twelve-month figure through Dec 2025 was -$6.0 million (down 22.72% YoY), and the FY2025 annual result was -$6.0 million, down 22.72% from the prior year.
• Common Equity came in at -$6.0 million for Q4 2025 at Guided Therapeutics, down from -$5.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$2.7 million in Q3 2022 to a low of -$8.0 million in Q1 2021.
• The 5-year median for Common Equity is -$5.0 million (2022), against an average of -$5.0 million.
• Across the five-year window, Common Equity surged 65.78% in 2022 and sank 40.78% in 2024, its largest moves.
• Guided Therapeutics' Common Equity stood at -$5.4 million in 2021, then soared by 47.05% to -$2.9 million in 2022, then plunged by 32.02% to -$3.8 million in 2023, then retreated by 28.46% to -$4.9 million in 2024, then dropped by 22.72% to -$6.0 million in 2025.
• The last three Common Equity figures came in at -$6.0 million (Q4 2025), -$5.7 million (Q3 2025), and -$5.5 million (Q2 2025), per Business Quant data.